Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Frederic Vanhoutte"'
Autor:
Andi Leubitz, Kate Banks, Kaela M. Porter, Frederic Vanhoutte, Ming‐yi Hu, Kathleen Campbell, Kathleen Tencer, Tom Haverty, Efrat Gordon
Publikováno v:
Clinical Pharmacology in Drug Development
ELX‐02 is an investigational compound being developed as a therapy for genetic diseases caused by nonsense mutations such as cystic fibrosis. Structurally, ELX‐02 is an aminoglycoside analogue that induces read‐through of nonsense mutations thr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc9c030d75a52de550ecdf3e8efe896
https://pubmed.ncbi.nlm.nih.gov/33465285
https://pubmed.ncbi.nlm.nih.gov/33465285
Autor:
Andrew Gewitz, Jeanne Mendell, Yuhuan Wang, Charles Harris, Benjamin A. Olenchock, Simona Podgrabinska, Wenjun Zheng, An Zhao, Hao Pan, Frédéric Vanhoutte, John D. Davis
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 4, Pp n/a-n/a (2024)
Abstract Mibavademab (previously known as REGN4461), a fully human monoclonal antibody, is being investigated for the treatment of conditions associated with leptin deficiency. Here, we report pharmacokinetics (PKs), pharmacodynamics, and immunogenic
Externí odkaz:
https://doaj.org/article/3a53c650addb4dff9fd51a0f804d2d33
Autor:
Frédéric Vanhoutte, Wen Liu, Richard T. Wiedmann, Liesbeth Haspeslagh, Xin Cao, Keith Boundy, Antonios Aliprantis, Michelle Davila, Jonathan Hartzel, Jianing Li, Mac McGuire, Katrin Ramsauer, Yvonne Tomberger, Roland Tschismarov, Deborah D. Brown, Weifeng Xu, Jeffrey R. Sachs, Kevin Russell, S. Aubrey Stoch, Eseng Lai
Publikováno v:
EBioMedicine, Vol 75, Iss , Pp 103811- (2022)
Summary: Background: We report on the safety and immunogenicity of V591, a measles vector-based SARS-CoV-2 vaccine candidate. Methods: In this multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial, healthy adults with no history
Externí odkaz:
https://doaj.org/article/d59aa9653c964fe6ac6e01ea17db7d32